Celsion Corporation (CLSN) Research Coverage Started at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. initiated coverage on shares of Celsion Corporation (NASDAQ:CLSN) in a research report released on Tuesday morning. The brokerage issued an outperform rating and a $9.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings also issued estimates for Celsion Corporation’s Q4 2017 earnings at ($0.29) EPS, FY2018 earnings at ($1.21) EPS, FY2019 earnings at ($1.32) EPS and FY2020 earnings at ($0.94) EPS.
CLSN has been the subject of several other research reports. Zacks Investment Research raised shares of Celsion Corporation from a hold rating to a buy rating and set a $1.50 price objective for the company in a research note on Tuesday, August 29th. ValuEngine raised shares of Celsion Corporation from a strong sell rating to a sell rating in a research note on Friday, September 1st. Finally, Maxim Group raised shares of Celsion Corporation from a hold rating to a buy rating and set a $7.00 price objective for the company in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $11.90.
Celsion Corporation (NASDAQ CLSN) opened at $3.13 on Tuesday. Celsion Corporation has a 12 month low of $1.24 and a 12 month high of $12.46.
A hedge fund recently bought a new stake in Celsion Corporation stock. Sabby Management LLC purchased a new position in Celsion Corporation (NASDAQ:CLSN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion Corporation as of its most recent SEC filing. 6.41% of the stock is currently owned by hedge funds and other institutional investors.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.